Minh Chau Thi Pham

Array ( [id] => 17830135 [patent_doc_number] => 20220267439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => Methods for Manipulating Phagocytosis Mediated by CD47 [patent_app_type] => utility [patent_app_number] => 17/736896 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308963 [patent_doc_number] => 20230112863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => IL-1 Binding Proteins [patent_app_type] => utility [patent_app_number] => 17/733303 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17733303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003599 [patent_doc_number] => 20220362365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => IMPROVED COMPOSITIONS AND METHODS FOR SHARED NEO-EPITOPE VACCINES [patent_app_type] => utility [patent_app_number] => 17/726946 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17726946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20491535 [patent_doc_number] => 12533390 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Methods and compositions for treatment of Endothelin B receptor expressing tumors [patent_app_type] => utility [patent_app_number] => 17/659545 [patent_app_country] => US [patent_app_date] => 2022-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 30 [patent_no_of_words] => 24142 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17659545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058971 [patent_doc_number] => 11938164 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Exosome-based cancer assays [patent_app_type] => utility [patent_app_number] => 17/714295 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 40 [patent_no_of_words] => 58598 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945765 [patent_doc_number] => 20220332782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => Combined Artificial Cell Death/Reporter System Polypeptide for Chimeric Antigen Receptor Cell and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/657803 [patent_app_country] => US [patent_app_date] => 2022-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17718987 [patent_doc_number] => 20220211706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => Methods and Compositions for Treating Cancer [patent_app_type] => utility [patent_app_number] => 17/701634 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056500 [patent_doc_number] => 20220387586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 [patent_app_type] => utility [patent_app_number] => 17/653846 [patent_app_country] => US [patent_app_date] => 2022-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17653846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19156088 [patent_doc_number] => 20240148795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => LYMPHANGIOGENESIS PROMOTING FACTOR-EXPRESSING FIBROBLAST, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME [patent_app_type] => utility [patent_app_number] => 18/548803 [patent_app_country] => US [patent_app_date] => 2022-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18548803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20213607 [patent_doc_number] => 12410249 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Low dose antibody-based methods for treating hematologic malignancies [patent_app_type] => utility [patent_app_number] => 17/679213 [patent_app_country] => US [patent_app_date] => 2022-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 6 [patent_no_of_words] => 1265 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17679213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17644681 [patent_doc_number] => 20220172420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => ANTI-HER3 ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/668904 [patent_app_country] => US [patent_app_date] => 2022-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668904 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865465 [patent_doc_number] => 20220288200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/584892 [patent_app_country] => US [patent_app_date] => 2022-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17584892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733374 [patent_doc_number] => 20220218833 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => PLATELET-FACILITATED DELIVERY OF THERAPEUTIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/581706 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17581706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533692 [patent_doc_number] => 20220112301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA [patent_app_type] => utility [patent_app_number] => 17/560006 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533632 [patent_doc_number] => 20220112241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => FOXM1-DERIVED PEPTIDE, AND VACCINE INCLUDING SAME [patent_app_type] => utility [patent_app_number] => 17/559991 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18085561 [patent_doc_number] => 11535679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma [patent_app_type] => utility [patent_app_number] => 17/558404 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 30348 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17558404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519333 [patent_doc_number] => 20220105181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => METHODS FOR IDENTIFYING BETA-GLUCAN BINDING TO IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 17/552137 [patent_app_country] => US [patent_app_date] => 2021-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828540 [patent_doc_number] => 20220265844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => DOSING REGIMENS FOR ANTI-TF-ANTIBODY DRUG-CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/548436 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18869857 [patent_doc_number] => 11857637 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Anti-CD25 antibody-maytansine conjugates and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/519183 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 14 [patent_no_of_words] => 35282 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 355 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546764 [patent_doc_number] => 20220118105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => CD38 Antibody Drug Conjugate [patent_app_type] => utility [patent_app_number] => 17/518375 [patent_app_country] => US [patent_app_date] => 2021-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17518375 [rel_patent_id] =>[rel_patent_doc_number] =>)